TWI821209B - 治療IgE介導的過敏性疾病 - Google Patents

治療IgE介導的過敏性疾病 Download PDF

Info

Publication number
TWI821209B
TWI821209B TW107138583A TW107138583A TWI821209B TW I821209 B TWI821209 B TW I821209B TW 107138583 A TW107138583 A TW 107138583A TW 107138583 A TW107138583 A TW 107138583A TW I821209 B TWI821209 B TW I821209B
Authority
TW
Taiwan
Prior art keywords
dose
antibody
ige
seq
antibodies
Prior art date
Application number
TW107138583A
Other languages
English (en)
Chinese (zh)
Other versions
TW201929899A (zh
Inventor
路孔明
陳念宜
鄭恬恬
Original Assignee
合一生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 合一生技股份有限公司 filed Critical 合一生技股份有限公司
Publication of TW201929899A publication Critical patent/TW201929899A/zh
Application granted granted Critical
Publication of TWI821209B publication Critical patent/TWI821209B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW107138583A 2017-10-31 2018-10-31 治療IgE介導的過敏性疾病 TWI821209B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579416P 2017-10-31 2017-10-31
US62/579,416 2017-10-31

Publications (2)

Publication Number Publication Date
TW201929899A TW201929899A (zh) 2019-08-01
TWI821209B true TWI821209B (zh) 2023-11-11

Family

ID=66332803

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107138583A TWI821209B (zh) 2017-10-31 2018-10-31 治療IgE介導的過敏性疾病

Country Status (13)

Country Link
US (2) US11439682B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703753A4 (cg-RX-API-DMAC7.html)
JP (1) JP7286665B2 (cg-RX-API-DMAC7.html)
KR (1) KR102859911B1 (cg-RX-API-DMAC7.html)
CN (1) CN111741768B (cg-RX-API-DMAC7.html)
AU (1) AU2018360999A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008488A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079992A1 (cg-RX-API-DMAC7.html)
IL (1) IL277911B2 (cg-RX-API-DMAC7.html)
MX (1) MX421215B (cg-RX-API-DMAC7.html)
TW (1) TWI821209B (cg-RX-API-DMAC7.html)
WO (1) WO2019085902A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002247B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304509A (zh) * 2021-04-02 2023-02-01 合一生技股份有限公司 高濃度抗體製劑
US20230122862A1 (en) * 2021-10-12 2023-04-20 United BioPharma, Inc. Treatment of ige-mediated diseases
CN114028731B (zh) * 2021-12-10 2024-01-26 固安翌光科技有限公司 腰部塑形光疗装置
EP4789727A1 (en) 2025-02-11 2026-08-12 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy of an ige-associated disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482351A (zh) * 2009-02-25 2012-05-30 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
CN104603150A (zh) * 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
EP0617127A1 (en) 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
WO1991004055A1 (en) 1989-09-15 1991-04-04 Tanox Biosystems, Inc. Treatment of autoimmune disease
DE69126607T2 (de) 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
US5281699A (en) 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
WO1992007574A1 (en) 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
EP0787150A1 (en) 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
AU3515597A (en) 1997-05-30 1998-12-30 Tanox Biosystems, Inc. Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide
EP2065052A3 (en) 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
AUPS158502A0 (en) 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
US20090220416A1 (en) 2006-05-03 2009-09-03 Sydney Welt Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
PL2132230T3 (pl) 2007-03-22 2014-09-30 Genentech Inc Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011108008A2 (en) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカAcademia Sinica Bリンパ球上のヒトmIgEに結合可能な抗CεmX抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482351A (zh) * 2009-02-25 2012-05-30 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
CN104603150A (zh) * 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Hobart W Walling et al., Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 3: doi: 10.2147/ccid.s6496. 2010 Jul 28; 99-117.; *
期刊 Mark Boguniewicz et al., Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol. 112(6 Suppl): doi: 10.1016/j.jaci.2003.09.031. 2003 Dec; S140-S150. *

Also Published As

Publication number Publication date
WO2019085902A1 (en) 2019-05-09
US12083161B2 (en) 2024-09-10
CN111741768B (zh) 2024-12-27
US11439682B2 (en) 2022-09-13
RU2020117749A3 (cg-RX-API-DMAC7.html) 2022-01-31
ZA202002247B (en) 2022-01-26
KR20200110302A (ko) 2020-09-23
RU2020117749A (ru) 2021-12-02
MX2020004469A (es) 2020-09-07
CA3079992A1 (en) 2019-05-09
CN111741768A (zh) 2020-10-02
IL277911A (en) 2020-11-30
IL277911B2 (en) 2025-07-01
EP3703753A1 (en) 2020-09-09
KR102859911B1 (ko) 2025-09-16
JP7286665B2 (ja) 2023-06-05
TW201929899A (zh) 2019-08-01
AU2018360999A1 (en) 2020-05-14
JP2021501213A (ja) 2021-01-14
US20200297815A1 (en) 2020-09-24
IL277911B1 (en) 2025-03-01
EP3703753A4 (en) 2021-08-18
BR112020008488A2 (pt) 2020-10-20
MX421215B (es) 2025-02-10
US20230100100A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
JP2026063214A (ja) 高濃度抗c5抗体製剤
US12083161B2 (en) Treating IgE-mediated allergic diseases
ES2897631T3 (es) Procedimientos para tratar o prevenir el asma mediante la administración de un antagonista de IL-4R
UA124269C2 (uk) Застосування антагоністу il-13 для лікування атопічного дерматиту
JP2004536072A (ja) 種々の疾患の治療のための抗−ngf抗体
CN115427450A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
CN116782934A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
EP3520803A1 (en) Novel uses
US8852588B2 (en) Treating allergic airway disorders using anti-IL-20 receptor antibodies
US20250059289A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
CA3153750A1 (en) Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2024311429A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
US20240336688A1 (en) Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
WO2022089595A1 (en) Biomarkers for ige-mediated diseases
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
US20080038252A1 (en) Histamine-Containing Composition for the Treatment of Allergic Diseases
RU2787595C2 (ru) Высококонцентрированные составы антител к c5
RU2847524C2 (ru) Высококонцентрированные составы антител к c5
HK40121853A (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
JP2025520177A (ja) IgG4関連疾患を治療するための方法および組成物
CN117715938A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
BR122023005826B1 (pt) Solução aquosa estável compreendendo um anticorpo anti-c5, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma